pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·44m ago·1 min read
save

FDA proposes new classification that formally recognizes NAC as a dietary ingredient, ending its legal gray area

Nov 16, 2026·read at STAT ↗RegulatoryPositive

The FDA announced a proposed rule that would create a new regulatory category for N-acetyl-L-cysteine (NAC), a product long sold as a dietary supplement.

Under the proposal, NAC would be classified as a "Dietary Ingredient Not Excluded from the Dietary Supplement Definition," effectively confirming its status as a supplement despite its prior drug approvals.

The change addresses a regulatory gap that arose because the agency had approved NAC as a drug in 1963 for mucus-breaking in lung conditions and in 1974 for treating acetaminophen overdose, and current rules bar approved drugs from being labeled as supplements.

Proponents, including members of the MAHA movement, view the rule as a victory that clarifies the market and removes uncertainty for manufacturers and consumers.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: In a win for MAHA, FDA creates new regulatory category for the supplement NAC”

read at STAT ↗
460 words · retrieved 8m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1h agoSTAT+: Expert warns of battleground over global access to newer GLP-1 drugs for obesitySTAT
  • 1h agoSTAT+: NIAID acting head John Powers III appointed as the permanent directorSTAT
  • 2h agoSTAT+: Biotech’s rebound isn’t lifting all boats equallySTAT
  • 2h agoSTAT+: Suing Joe the Plumber and Microsoft, and diminishing raisesSTAT
  • 5h agoSTAT+: Pharmalittle: We’re reading about GLP-1 use, Covid-19 vaccine investment returns, and moreSTAT